AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 92 min read$OPCH

Option Care Health (OPCH) Faces Legal Review Of Its Proposed Takeover

Option Care Health (OPCH) is under investigation by securities law firms regarding its proposed sale to Clayton, Dubilier & Rice and McKesson Corporation. The firms are probing whether OPCH's board secured a fair price and process for investors. The deal, valued at approximately $4.6 billion, includes a 37% upfront premium and a $291.9 million reverse break fee. The shareholder vote on the merger agreement is a key upcoming event.

Original reporting
finance.yahoo.com
Published Oct 9, 2026, 2:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 9, 2026, 2:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Option Care Health (OPCH) Faces Legal Review Of Its Proposed Takeover — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$OPCHBearishLow
01

Why it matters

Legal reviews could delay or alter the transaction terms, affecting shareholder value.

02

Market read

The investigation adds risk to a pending M&A, likely influencing OPCH's share price and sector sentiment.

03

What to watch

Potential synergies with McKesson and CD&R may offset short‑term legal concerns.

Relevance 6/10Novelty 5/10Timing: today

Background

Option Care Health provides home and alternate site infusion services; the proposed sale values the company at about $4.6 billion.

Company-level read

Ticker impact

$OPCHBearishMedium confidence
Context

Option Care Health is under shareholder investigations into its proposed $32.05 per share sale to Clayton, Dubilier & Rice and McKesson, raising questions about deal fairness.

Expected impact

downward pressure as investors weigh potential deal delays or renegotiation.

Evidence & confidence

The article introduces new regulatory scrutiny that could affect deal completion and valuation.

Market effects

Sector

The home infusion services sector may see heightened scrutiny on M&A activity.

Regional

U.S. healthcare services market could experience modest volatility.

Global

Limited to U.S. healthcare investors.

Counterpoint

What could challenge this read

If the probes are superficial, the deal could still close at the agreed premium, supporting upside.

Key entities

  • company
    Option Care Health

    Target of the proposed sale.

  • private equity firm
    Clayton, Dubilier & Rice

    Potential acquirer.

  • company
    McKesson Corporation

    Potential co‑buyer.

Read at source← All news

Related articles

OCT 30
$BTSGHighAI 9/10

BrightSpring Soars 12% on Q3 Beat and Raised 2026 Guidance as Adjusted EBITDA Jumps 42%

BrightSpring Health Services (BTSG) stock rose 12% after Q3 earnings beat estimates, with revenue up 26% to $4.21B and adjusted EBITDA up 42% to $228M. The company raised its 2026 guidance. Gross profit per script increased 27%, and home health census grew 58% due to acquisitions from UnitedHealth's Amedisys and LHC Group. Option Care Health (OPCH) and CVS Health (CVS) report next week, which may indicate if BrightSpring's pricing gains are industry-wide.

finance.yahoo.com6 min
OCT 10
$OPCHMed

Key deals this week: Option Care Health, PTC, Energy Transfer and more

Service Properties Trust (SSVC) received a $2.0B acquisition offer from TKO LLC. Viatris (VTRS) agreed to buy Pacira BioSciences (PCRX) for $1.65B. Option Care Health (OPCH) surged 34% after a $5.8B acquisition deal with CD&R and McKesson (MCK). Energy Transfer (ET) will acquire Vaquero Midstream for $2.625B. Emera (EMA) and Canadian Utilities (CDUAF) agreed to a $10B merger. Cenovus Energy (CVE) will acquire Athabasca Oil (ATHOF) for ~$5.7B.

tradingview.com1 min
OCT 10
$OPCHHighAI 9/10

Option Care Health Sold for $5.8B in CD&R-McKesson Deal

Option Care Health (OPCH) is being acquired by CD&R and McKesson (MCK) for $5.8B, or $32.05 per share, a 37% premium. The deal, expected to close in 2027, values the company at $5.8B. Option Care Health will operate independently post-acquisition. The company reported $5.6B in 2025 revenue and $207.6M in net income, with modest growth in 2026. The acquisition aligns with McKesson's strategy to expand access to innovative therapies.

hoodline.com2 min
OCT 9
$MCKHighAI 9/10

McKesson (MCK) Joins $5.8 Billion Option Care Health (OPCH) Acquisition. Is the Valuation Justified?

McKesson (MCK) is acquiring Option Care Health (OPCH) for $5.8B, including debt, at $32.05 per share, a 37% premium. McKesson and private equity firm CD&R will own 49% and 51% respectively. The deal expands McKesson's specialty healthcare services. McKesson's Q1 2027 revenue was $105.4B, beating estimates, with adjusted EPS up 20% YoY to $9.93. The company raised its fiscal 2027 adjusted EPS guidance to $44.20-$45.00.

finance.yahoo.com2 min
OCT 7
$OPCHHighAI 9/10

Infusion therapy provider being acquired in $5.8 billion deal

Option Care Health (OPCH) is being acquired by CD&R and McKesson in a $5.8 billion deal, expected to close in early 2027. CD&R will hold majority ownership, with McKesson holding a minority stake. Option Care Health shares were trading at $31.02, up from $23.34 before the acquisition news. The company will remain separate but will delist from Nasdaq post-deal.

wfmz.com2 min